MAPK3

Mitogen-activated protein kinase 3

94,889 patent compounds predicted against MAPK3, 67,987 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL175868	0.57	13/20
SCHEMBL176745	0.40	6/20
SCHEMBL375776	0.46	5/20
SCHEMBL384627	0.39	5/20
SCHEMBL198191	0.45	4/20
SCHEMBL354708	0.43	4/20
SCHEMBL354709	0.43	4/20
SCHEMBL270785	0.52	3/20
SCHEMBL254659	0.48	3/20
SCHEMBL173902	0.46	3/20
SCHEMBL173378	0.46	3/20
SCHEMBL174405	0.46	3/20
SCHEMBL173673	0.45	3/20
SCHEMBL176600	0.39	3/20
SCHEMBL176624	0.39	3/20
SCHEMBL176651	0.39	3/20
SCHEMBL176719	0.39	3/20
SCHEMBL176781	0.39	3/20
SCHEMBL178152	0.39	3/20
Purvalanol B (SCHEMBL27951)	1.00	2/20

Germline variants in MAPK3 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MAPK3 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MAPK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation	PHASE4	ACTIVE_NOT_RECRUITING
Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility.	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	PHASE2	COMPLETED
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS	PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer	PHASE2	COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	PHASE2	UNKNOWN
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors	PHASE1	COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients	PHASE1	UNKNOWN
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	PHASE1	COMPLETED
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer	PHASE1	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation	nan	COMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Muscle Wasting in Cancer (MWIC)	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED
Histiocytic Disorder Follow-up Study	nan	RECRUITING
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAPK3 binder may also engage these)

Protein	Name	Similarity
P21708	—	1.000	P21708 →
Q63844	—	1.000	Q63844 →
P26696	—	0.991	P26696 →
MAPK1	Mitogen-activated protein kinase 1	0.990	landscape →
P63086	—	0.990	P63086 →
A0A423WA64	—	0.987	A0A423WA64 →
P63085	—	0.987	P63085 →
G9MQI4	—	0.987	G9MQI4 →
A0A5B9GBF0	—	0.987	A0A5B9GBF0 →
P46196	—	0.986	P46196 →
Q336X9	—	0.986	Q336X9 →
Q6Z437	—	0.986	Q6Z437 →
Q40884	—	0.986	Q40884 →
Q0D0P5	—	0.986	Q0D0P5 →
P40417	—	0.986	P40417 →
Q1DUU8	—	0.985	Q1DUU8 →
Q0U4L8	—	0.985	Q0U4L8 →
P27638	—	0.985	P27638 →
Q56R42	—	0.985	Q56R42 →
Q00859	—	0.985	Q00859 →
O42781	—	0.985	O42781 →
Q4PC06	—	0.985	Q4PC06 →
P0CP69	—	0.984	P0CP69 →
Q39022	—	0.984	Q39022 →
Q38HL5	—	0.984	Q38HL5 →
G4N0Z0	—	0.984	G4N0Z0 →
Q8TGA9	—	0.984	Q8TGA9 →
Q8NJT7	—	0.984	Q8NJT7 →
Q39024	—	0.984	Q39024 →
Q92246	—	0.984	Q92246 →